Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UMC119-06 in Acute Respiratory Distress Syndrome (ARDS)
NCT04347967Phase 1Not yet recruiting
- Sponsor
- Meridigen Biotech Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umc119-06 in acute respiratory distress syndrome (ARDS), sponsored by Meridigen Biotech Co., Ltd. Primary endpoint: Incidence and frequency of adverse events at 3 months. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
umc119-06
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04347967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347967.